SAN DIEGO, Jan. 31, 2017 — Medical Marijuana, Inc. (OTC PINK: MJNA), the first publicly traded cannabis company in the United States, is proud to announce the progress made by subsidiary HempMeds® Mexico upon the one-year anniversary of the first-ever import permit for RSHO-X™ into Mexico.
HempMeds® Mexico is the first company to receive government import permits for the cannabidiol (CBD) oil product RSHO-X™ via the Mexican Health Department, COFEPRIS. The decision by COFEPRIS ushered in a historic newfound relationship between the company and Mexico.
The first permits issued for usage of the CBD product were for two Mexico girls Alina Maldonado Montes de Oca and Maria Paula. The plight of parents attempting to acquire CBD hemp oil products for their suffering children was profiled in the documentary Crisis, which features HempMeds® Mexico and the legal battle for access to CBD products.
HempMeds® Mexico hosted the country’s first-ever Doctors Symposium in Mexico City aimed at educating medical professionals on the benefits of CBD and the proper way to prescribe it. The company has since partaken in numerous events like the First National Symposium to meet with political and advocacy leaders. These events serve as a means of community outreach and promote further access to CBD hemp oil products amongst citizens of Mexico, and have helped educate thousands of doctors and patients alike on the company’s products.
Another family close to HempMeds® Mexico is that of Grace of the Por Grace Foundation. Grace’s father, Raul Elizalde, started the Por Grace Foundation to further access to CBD for Grace and others like his daughter. The premier cannabidiol advocacy group works closely with HempMeds® Mexico to help interested patients navigate the process to access CBD. Raul was invited to join President Peña Nieto on stage in April to give an impassioned speech about the effects of cannabinoids on his daughter before the Mexican President announced that country would be pursuing a more compassionate stance on the medical use of marijuana in the country.
These initial permits have enabled product access for more than 126 million people in Mexico. As the demand and popularity of the company’s products have begun to soar, new appointments to leadership were also introduced. In August of 2016, Dion Markgraaff was named President of HempMeds® Mexico in order to sustain and promote the growth of the company’s development in the country.
“We are proud to see the expanding presence of RSHO-X™ within Mexico,” said Medical Marijuana, Inc. CEO, Dr. Stuart Titus. “A short year ago, we were providing our product to two patients in Mexico. Now, we are pleased to see that over 200 people have begun to experience the value of what our company has to offer.”
Dr. Titus added, “HempMeds® Mexico serves an invaluable purpose to those in Mexico who suffer needlessly in silence. We expect and fully commit to continued growth in our southern neighbor so that we can strengthen the lives and livelihoods of those we serve.”
HempMeds® RSHO-X™ CBD oil was also at the center of a recent study on the effects of CBD and epilepsy. Renowned Mexican physician Dr. Carlos G. Aguirre Velazquez recently announced the results of a new survey conducted on children with refractory epilepsy.
HempMeds® Mexico, which established itself in Monterrey, Nuevo Leon, seeks to continue working with Mexican health authorities in beginning clinical studies on CBD products in 2017.
HempMeds® Mexico also worked to open several new Latin American markets this past year, expanding efforts into Chile, Colombia, and Paraguay. As the tide of opinion regarding medical marijuana continues to change in Latin America, HempMeds® Mexico and Medical Marijuana, Inc. will work alongside activists and patients in efforts to bring access to those who need it most.
About HempMeds® Mexico
HempMeds®Mexico is a Mexico-based company that made history by being the first company to receive a COFEPRIS federal government import permit for the cannabis product RSHO-X™ for a medical indication. HempMeds® Mexico plans to work directly with the Mexican government to safely and legally provide access to CBD hemp oil products. For more information, please review the company’s website at: http://www.hempmeds.mx.
About Medical Marijuana, Inc.
Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.
FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE
These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.
Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.